Akcea Therapeutics, Inc. (AKCA)
| Market Cap | 1.85B |
| Revenue (ttm) | 336.55M |
| Net Income (ttm) | -41.52M |
| Shares Out | 101.48M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Oct 12, 2020 |
| Last Price | $18.17 |
| Previous Close | $18.17 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 18.13 - 18.17 |
| Day's Volume | 0 |
| 52-Week Range | 8.00 - 21.71 |
News
NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the f...
NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the...
LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc.
PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
SAN DIEGO, Sept. 1, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Akcea Therapeutics, Inc.
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc.
(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders ewsfilecorp.com...
Akcea Therapeutics Inc. (NASDAQ: AKCA) stock jumped on Monday after it was announced that Ionis Pharmaceuticals Inc.
Akcea Therapeutics Inc (NASDAQ: AKCA) shares were rallying strongly Monday following a buyout deal.
CARLSBAD, Calif. and BOSTON, Aug.
Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q2 2020 Results - Earnings Call Transcript
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...
BOSTON, Aug. 4, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
BOSTON, July 20, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
BOSTON, July 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joi...
Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near t...
BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to trea...
Akcea: Uninteresting Slow Growth Stock With Long-Term Potential
BOSTON, June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined ...
BOSTON, June 8, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Age...
BOSTON, June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Auth...
Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) ex...
BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the co...
BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS)...
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q1 2020 Results - Earnings Call Transcript
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has...
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., ...
Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q4 2019 Results - Earnings Call Transcript
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman...
Both primary as well as multiple secondary endpoints were met in the trial.
Favorable safety and tolerability were observed
The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.
Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study. The post Will These ...
Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease st...
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, ...
Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile
Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020
Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board
Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.
Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience ...
About AKCA
Akcea Therapeutics, a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCE... [Read more...]
| Industry Biotechnology | IPO Date Jul 14, 2017 |
| CEO Damien McDevitt | Employees 294 |
| Stock Exchange NASDAQ | Ticker Symbol AKCA |